Page 113 - Read Online

Page 12 of 12 Zhang et al. Hepatoma Res 2020;6:40 I http://dx.doi.org/10.20517/2394-5079.2020.20

for hepatocellular carcinoma: safety and efficacy. Nan Fang Yi Ke Da Xue Xue Bao 2014;34:674-8.
115. He G, Zheng C, Huo H, Zhang H, Zhu Z, et al. TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of
hepatocellular carcinoma: a meta-analysis. Int Immunopharmacol 2016;40:436-42.
116. Zhou Z, Qin H, Weng L, Ni Y. Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular
carcinoma. J Buon 2019;24:615-21.
117. Gonzalez-Carmona MA, Marten A, Hoffmann P, Schneider C, Sievers E, et al. Patient-derived dendritic cells transduced with an
a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune
response against hepatocellular carcinoma cells. Liver Int 2006;26:369-79.
118. Yu X, Xia W, Zhang T, Wang H, Xie Y, et al. Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-
induced killer cells to hepatocellular carcinoma cells. Int J Hematol 2010;92:276-82.
119. Wang Y, Wang Y, Mu H, Liu T, Chen X, et al. Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3
gene and co-cultured with cytokine-induced killer cells against hepatocellular carcinoma cells. Mol Med Rep 2015;11:3361-7.